Clinical Trials · NCT00308139
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 303
- Start date
- Apr 2006
- Locations
- 25 sites, United States, Canada
- Primary endpoint
- Change in HbA1c From Baseline to Week 30